Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy
Microglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke. Microglia become “activated”, proliferating, and undergoing changes in morphology, gene and protein expression over days and w...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/10/3/159 |
id |
doaj-5dde04d0ab254f05b8a46fbcbaa2adef |
---|---|
record_format |
Article |
spelling |
doaj-5dde04d0ab254f05b8a46fbcbaa2adef2020-11-25T03:10:05ZengMDPI AGBrain Sciences2076-34252020-03-0110315910.3390/brainsci10030159brainsci10030159Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke TherapyCharlotte Rawlinson0Stuart Jenkins1Laura Thei2Mark L. Dallas3Ruoli Chen4School of Pharmacy and Bioengineering, Keele University, Staffordshire ST5 5BG, UKSchool of Medicine, Keele University, Staffordshire ST5 5BG, UKSchool of Pharmacy, University of Reading, Reading RG6 6UB, UKSchool of Pharmacy, University of Reading, Reading RG6 6UB, UKSchool of Pharmacy and Bioengineering, Keele University, Staffordshire ST5 5BG, UKMicroglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke. Microglia become “activated”, proliferating, and undergoing changes in morphology, gene and protein expression over days and weeks post-ischaemia, with deleterious and beneficial effects. Pro-inflammatory microglia (commonly referred to as M1) exacerbate secondary neuronal injury through the release of reactive oxygen species, cytokines and proteases. In contrast, microglia may facilitate neuronal recovery via tissue and vascular remodelling, through the secretion of anti-inflammatory cytokines and growth factors (a profile often termed M2). This M1/M2 nomenclature does not fully account for the microglial heterogeneity in the ischaemic brain, with some simultaneous expression of both M1 and M2 markers at the single-cell level. Understanding and regulating microglial activation status, reducing detrimental and promoting repair behaviours, present the potential for therapeutic intervention, and open a longer window of opportunity than offered by acute neuroprotective strategies. Pharmacological modulation of microglial activation status to promote anti-inflammatory gene expression can increase neurogenesis and improve functional recovery post-stroke, based on promising preclinical data. Cell-based therapies, using preconditioned microglia, are of interest as a method of therapeutic modulation of the post-ischaemic inflammatory response. Currently, there are no clinically-approved pharmacological options targeting post-ischaemic inflammation. A major developmental challenge for clinical translation will be the selective suppression of the deleterious effects of microglial activity after stroke whilst retaining (or enhancing) the neurovascular repair and remodelling responses of microglia.https://www.mdpi.com/2076-3425/10/3/159ischaemic strokeneuroinflammationmicrogliapro-inflammatoryanti-inflammatoryphenotype |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Charlotte Rawlinson Stuart Jenkins Laura Thei Mark L. Dallas Ruoli Chen |
spellingShingle |
Charlotte Rawlinson Stuart Jenkins Laura Thei Mark L. Dallas Ruoli Chen Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy Brain Sciences ischaemic stroke neuroinflammation microglia pro-inflammatory anti-inflammatory phenotype |
author_facet |
Charlotte Rawlinson Stuart Jenkins Laura Thei Mark L. Dallas Ruoli Chen |
author_sort |
Charlotte Rawlinson |
title |
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy |
title_short |
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy |
title_full |
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy |
title_fullStr |
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy |
title_full_unstemmed |
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy |
title_sort |
post-ischaemic immunological response in the brain: targeting microglia in ischaemic stroke therapy |
publisher |
MDPI AG |
series |
Brain Sciences |
issn |
2076-3425 |
publishDate |
2020-03-01 |
description |
Microglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke. Microglia become “activated”, proliferating, and undergoing changes in morphology, gene and protein expression over days and weeks post-ischaemia, with deleterious and beneficial effects. Pro-inflammatory microglia (commonly referred to as M1) exacerbate secondary neuronal injury through the release of reactive oxygen species, cytokines and proteases. In contrast, microglia may facilitate neuronal recovery via tissue and vascular remodelling, through the secretion of anti-inflammatory cytokines and growth factors (a profile often termed M2). This M1/M2 nomenclature does not fully account for the microglial heterogeneity in the ischaemic brain, with some simultaneous expression of both M1 and M2 markers at the single-cell level. Understanding and regulating microglial activation status, reducing detrimental and promoting repair behaviours, present the potential for therapeutic intervention, and open a longer window of opportunity than offered by acute neuroprotective strategies. Pharmacological modulation of microglial activation status to promote anti-inflammatory gene expression can increase neurogenesis and improve functional recovery post-stroke, based on promising preclinical data. Cell-based therapies, using preconditioned microglia, are of interest as a method of therapeutic modulation of the post-ischaemic inflammatory response. Currently, there are no clinically-approved pharmacological options targeting post-ischaemic inflammation. A major developmental challenge for clinical translation will be the selective suppression of the deleterious effects of microglial activity after stroke whilst retaining (or enhancing) the neurovascular repair and remodelling responses of microglia. |
topic |
ischaemic stroke neuroinflammation microglia pro-inflammatory anti-inflammatory phenotype |
url |
https://www.mdpi.com/2076-3425/10/3/159 |
work_keys_str_mv |
AT charlotterawlinson postischaemicimmunologicalresponseinthebraintargetingmicrogliainischaemicstroketherapy AT stuartjenkins postischaemicimmunologicalresponseinthebraintargetingmicrogliainischaemicstroketherapy AT laurathei postischaemicimmunologicalresponseinthebraintargetingmicrogliainischaemicstroketherapy AT markldallas postischaemicimmunologicalresponseinthebraintargetingmicrogliainischaemicstroketherapy AT ruolichen postischaemicimmunologicalresponseinthebraintargetingmicrogliainischaemicstroketherapy |
_version_ |
1724660684561580032 |